secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001213900-25-110878
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Q3 net loss $2.1M; revenue down 38% YoY to $3.4M on generic competition
------------------------------------------------------------------------------

- Net loss of $2.1M ($0.03/share) vs net income of $1.8M in Q3 2024.
- Revenue fell 38% to $3.4M from $5.5M; decline driven by generic L-Glutamine in U.S. and lower MENA sales.
- Operating expenses reduced 43% to $2.4M due to workforce reduction and cost cuts.
- Income from operations $0.7M vs $0.8M prior year, partially offsetting revenue drop.
- Cash and equivalents dropped to $0.3M at Sept 30 from $1.4M at Dec 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390025110878/0001213900-25-110878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390025110878/ea0265516-8k_emmaus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-110878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer